US biopharmaceutical company AbbVie opened a biologics manufacturing facility within its plant located at the Tuas Biomedical Park.
Biologics are commercial products, such as vaccines, derived from biotechnology. The opening marked the completion of AbbVie’s S$400m plant at Tuas – its first manufacturing plant in Asia that was officially opened last September.
The 120,000 square metres plant is also home to a small molecule active pharmaceutical ingredients (API) facility, which is already up and running. Together, the two facilities will create 250 jobs in various roles, such as supply chain management, technical operations and manufacturing.